Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Boor Kathryn JeanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-761Price:$122.93
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Wigzell Hans Lennart RudolfOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-15,000Price:--
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Wigzell Hans Lennart RudolfOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-100Price:$122.39
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Wigzell Hans Lennart RudolfOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-11,745Price:$123.10
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Wigzell Hans Lennart RudolfOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,155Price:$123.85
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Wigzell Hans Lennart RudolfOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:15,000Price:$13.90
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Arif BilalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-472Price:$123.14
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Rodino-Klapac LouiseOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-909Price:$123.14
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Brown Ryan EdwardOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-899Price:$123.14
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Estepan Ian MichaelOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,035Price:$123.14
Filings by filing date
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Wigzell Hans Lennart RudolfOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-15,000Price:--
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Wigzell Hans Lennart RudolfOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-100Price:$122.39
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Wigzell Hans Lennart RudolfOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-11,745Price:$123.10
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Wigzell Hans Lennart RudolfOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,155Price:$123.85
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Wigzell Hans Lennart RudolfOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:15,000Price:$13.90
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Arif BilalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-472Price:$123.14
-
Mar 07, 2024 (filed on Mar 11, 2024)Insider Name:Arif BilalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-506Price:$120.49
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Rodino-Klapac LouiseOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-909Price:$123.14
-
Mar 07, 2024 (filed on Mar 11, 2024)Insider Name:Rodino-Klapac LouiseOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-512Price:$120.49
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Boor Kathryn JeanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-761Price:$122.93
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 215 1st St Ste 415 CAMBRIDGE MA 02142-1213 |
Tel: | N/A |
Website: | https://www.sarepta.com |
IR: | See website |
Key People | ||
Douglas S. Ingram President, Chief Executive Officer, Director | Ian Michael Estepan Chief Financial Officer, Executive Vice President | Louise Rodino-Klapac Executive Vice President, Chief Scientific Officer, Head of R and D |
Ryan E. Brown Executive Vice President, General Counsel, Corporate Secretary | Bilal Arif Executive Vice President - Strategy and Operations, Chief Technical Operations Officer |
Business Overview |
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development. |
Financial Overview |
For the fiscal year ended 31 December 2023, Sarepta Therapeutics Inc revenues increased 33% to $1.24B. Net loss decreased 24% to $536M. Revenues reflect Product, net increase of 36% to $1.14B, Collaboration and other increase of 10% to $98.5M. Lower net loss reflects Pharmaceutical segment loss decrease of 50% to $267.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$8.03 to -$5.80. |
Employees: | 1,314 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $11,223M as of Dec 31, 2023 |
Annual revenue (TTM): | $1,243M as of Dec 31, 2023 |
EBITDA (TTM): | -$223.43M as of Dec 31, 2023 |
Net annual income (TTM): | -$535.98M as of Dec 31, 2023 |
Free cash flow (TTM): | -$588.34M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 93,855,410 as of Feb 23, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |